IL6 and myeloid sarcoma: Finally, CSF IL-6 (Figure 3C) seemed to be a good biomarker to distinguish MS from NMOSD/MOGAD (median CSF IL-6 of 3.1 vs. 27.0 pg/ml for MS and NMOSD/MOGAD, respectively, p < 0.001) and from CNS vasculitis (median CSF IL-6 for vasculitis of 27.7 pg/ml, p < 0.001).